“Association Between Baseline Disease Characteristics and Relapse-Free Survival in Patients With BRAF V600–Mutant Resected Stage III Melanoma Treated With Adjuvant Dabrafenib + Trametinib or Placebo”. 2019. SKIN The Journal of Cutaneous Medicine 3 (November): S53. https://doi.org/10.25251/skin.3.supp.53.